Human paraoxonase-1 activity is related to the number of CD4+ T-cells and is restored by antiretroviral therapy in HIV-1-infected individuals
- PMID: 24719500
- PMCID: PMC3955638
- DOI: 10.1155/2014/480201
Human paraoxonase-1 activity is related to the number of CD4+ T-cells and is restored by antiretroviral therapy in HIV-1-infected individuals
Abstract
Background: Paraoxonase-1 (PON1) activity is suggested to be altered in individuals infected with human immunodeficiency virus type-1 (HIV-1). We investigated PON1 activity in individuals receiving different regimens of highly active antiretroviral therapy (HAART).
Methods: PON1 activity was evaluated in 91 HIV-1 seronegative and 624 HIV-1 infected individuals (115 were not undergoing therapy (ART-naïve), and 509 were receiving HAART). HIV-1 infected individuals were treated with the following: efavirenz (EFV; n = 195) or nevirapine (NVP; n = 95) or lopinavir/ritonavir (LOP/r; n = 219). Serum levels of total cholesterol (TC), HDL, and low-density lipoprotein (LDL) fractions and the atherogenic indices (AI, TC : HDL, and LDL : HDL ratios) were determined.
Results: PON1 activity (U/L) was lower in the ART-naïve group compared with the other groups. PON1 activity correlated with CD4+ T-cell number of ART-naïve group (r = 0,121; P = 0,014). The LOP/r group showed a reduction in HDL and an increase in AI (TC : HDL ratio) in comparison with other groups.
Conclusion: PON1 activity was reduced in untreated individuals, but not in individuals receiving HAART. PON1 activity correlated with the number of CD4+ T-cells. The findings suggest that the activity of PON1 is associated with the immune status of HIV-1 infected individuals.
Similar articles
-
Serum levels of IgG antibodies against oxidized LDL and atherogenic indices in HIV-1-infected patients treated with protease inhibitors.Clin Chem Lab Med. 2013 Feb;51(2):371-8. doi: 10.1515/cclm-2012-0225. Clin Chem Lab Med. 2013. PMID: 23241595
-
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.PLoS Med. 2004 Oct;1(1):e19. doi: 10.1371/journal.pmed.0010019. Epub 2004 Oct 19. PLoS Med. 2004. PMID: 15526045 Free PMC article. Clinical Trial.
-
Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico.J Acquir Immune Defic Syndr. 2010 Apr;53(5):582-8. doi: 10.1097/QAI.0b013e3181cae4a1. J Acquir Immune Defic Syndr. 2010. PMID: 20090545 Clinical Trial.
-
Prevalence of dyslipidaemia among HIV-infected patients receiving combination antiretroviral therapy in North Shewa, Ethiopia.PLoS One. 2021 Apr 27;16(4):e0250328. doi: 10.1371/journal.pone.0250328. eCollection 2021. PLoS One. 2021. PMID: 33905435 Free PMC article.
-
Lipid peroxidation and total cholesterol in HAART-naïve patients infected with circulating recombinant forms of human immunodeficiency virus type-1 in Cameroon.PLoS One. 2013 Jun 7;8(6):e65126. doi: 10.1371/journal.pone.0065126. Print 2013. PLoS One. 2013. PMID: 23762297 Free PMC article.
Cited by
-
Current Understanding of the Immunomodulatory Activities of High-Density Lipoproteins.Biomedicines. 2021 May 21;9(6):587. doi: 10.3390/biomedicines9060587. Biomedicines. 2021. PMID: 34064071 Free PMC article. Review.
-
Native High-Density Lipoproteins (HDL) with Higher Paraoxonase Exerts a Potent Antiviral Effect against SARS-CoV-2 (COVID-19), While Glycated HDL Lost the Antiviral Activity.Antioxidants (Basel). 2021 Feb 1;10(2):209. doi: 10.3390/antiox10020209. Antioxidants (Basel). 2021. PMID: 33535459 Free PMC article.
-
PON-1 and PON-2 Polymorphisms and PON-1 Paraoxonase Activity in People Living with HIV-1.Antioxidants (Basel). 2025 Feb 12;14(2):209. doi: 10.3390/antiox14020209. Antioxidants (Basel). 2025. PMID: 40002395 Free PMC article.
-
Paraoxonases Activities and Polymorphisms in Elderly and Old-Age Diseases: An Overview.Antioxidants (Basel). 2019 May 2;8(5):118. doi: 10.3390/antiox8050118. Antioxidants (Basel). 2019. PMID: 31052559 Free PMC article. Review.
-
Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.World J Virol. 2015 May 12;4(2):56-77. doi: 10.5501/wjv.v4.i2.56. World J Virol. 2015. PMID: 25964872 Free PMC article. Review.
References
-
- Riddler SA, Li X, Chu H, et al. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Medicine. 2007;8(5):280–287. - PubMed
-
- Negredo E, Paredes R, Peraire J, et al. Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study. Antiviral Therapy. 2004;9(6):889–893. - PubMed
-
- Wang X, Chai H, Yao Q, Chen C. Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. Journal of Acquired Immune Deficiency Syndromes. 2007;44(5):493–499. - PubMed
-
- Hui DY. Effects of HIV protease inhibitor therapy on lipid metabolism. Progress in Lipid Research. 2003;42(2):81–92. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous